Content area

|
|

Vurdering af effekt og sikkerhed ved rimonabant som farmakologisk behandling af adipositas

Forfatter(e)
Cand.scient. Robin Christensen, levnedsmiddelingeniør Pernelle Kruse Kristensen, dr.scient. Else Marie Bartels, professor Henning Bliddal & professor Arne Astrup Frederiksberg Hospital, Parker Instituttet, Københavns Universitet, Det Biovidenskabelige Fakultet, Institut for Human Ernæring, og Københavns Universitetsbibliotek
Reference: 
Ugeskr Læger 2007;169(50):4360-4363
Blad nummer: 
Sidetal: 
4360-4363
Summary A meta-analysis of the efficacy and safety of the anti-obesity agent Rimonabant: Ugeskr Læger 2007;169(50):4360-4363 A meta-analysis of all randomised controlled trials examining the efficacy and safety of the anti-obesity agent Rimonabant (Acomplia, 20 mg/d) found an efficacy of 4.7 kg (4.1-5.3) more weight loss after one year compared to placebo. Rimonabant increased the risk of adverse events, including depressive episodes and anxiety, despite depressive symptoms being an exclusion criterion in these trials. This, combined with an increased risk of suicidality during Rimonabant treatment, warrants increased awareness from prescribing physicians.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Torben Mahneke | 22/10
1 Kommentar
af Flemming Amter | 19/10
1 Kommentar
af Henrik Dibbern | 18/10
1 Kommentar
af Jens Langhoff-Roos | 17/10
3 kommentarer
af Tomas Christensen Kjær | 16/10
1 Kommentar
af Lars Lindberg Andersen | 15/10
1 Kommentar
af Johan Tommy Robert Wallentin | 14/10
1 Kommentar